{"organizations": [], "uuid": "4ee2edbd49344db0ed14da1b5aa52601a6260401", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-exelixis-announces-results-from-a/brief-exelixis-announces-results-from-a-phase-2-trial-of-cabozantinib-in-the-first-line-treatment-of-metastatic-radioiodine-refractory-differentiated-thyroid-carcinoma-idUSASB0C5HV", "country": "US", "domain_rank": 408, "title": "Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.035, "site_type": "news", "published": "2018-02-14T05:24:00.000+02:00", "replies_count": 0, "uuid": "4ee2edbd49344db0ed14da1b5aa52601a6260401"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-exelixis-announces-results-from-a/brief-exelixis-announces-results-from-a-phase-2-trial-of-cabozantinib-in-the-first-line-treatment-of-metastatic-radioiodine-refractory-differentiated-thyroid-carcinoma-idUSASB0C5HV", "ord_in_thread": 0, "title": "Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "exelixis inc", "sentiment": "neutral"}, {"name": "exelixis", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Exelixis Inc:\n* EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA\n* EXELIXIS INC - ‍EXELIXIS PLANS TO INITIATE A PIVOTAL PHASE 3 TRIAL LATER THIS YEAR​\n* EXELIXIS INC - ‍54 PERCENT OBJECTIVE RESPONSE RATE AND 43 PERCENT STABLE DISEASE OBSERVED AMONG 35 EVALUABLE PATIENTS​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T05:24:00.000+02:00", "crawled": "2018-02-14T12:36:48.000+02:00", "highlightTitle": ""}